GlaxoSmithKline plc
Notification of Transactions of Directors and Persons Discharging Managerial Responsibility
GlaxoSmithKline Performance Share Plan
Sale of shares to meet tax liabilities
The table below sets out changes in the interests of Directors and Persons Discharging Managerial Responsibilities ('PDMR') in the Ordinary Shares of GlaxoSmithKline plc arising from the sale of Ordinary Shares at a fair market value price of £14.06 per Ordinary Share on 12 February 2016 to meet tax liabilities following the vesting of awards granted in 2012 under the GlaxoSmithKline 2009 Performance Share Plan ('PSP').
Director/PDMR |
Number of Ordinary Shares sold to meet tax liabilities following the vesting of a PSP award |
Sir Andrew Witty* |
68,158 |
Mr S Dingemans* |
39,987 |
Mr R Connor |
17,134 |
Mr A Hussain |
24,104 |
Mr D Redfern |
13,136 |
Ms C Thomas |
18,562 |
Mr P Thomson |
8,853 |
Dr P Vallance |
39,979 |
Ms E Walmsley |
22,845 |
Mrs VA Whyte** |
2,451 |
* Denotes an Executive Director
** Sale for tax of vested PSP awards granted under the non CET Performance Share Plan
The table below sets out changes in the interests of PDMRs in the American Depositary Shares ('ADS') of GlaxoSmithKline plc arising from the withholding of ADSs at a closing share price of $39.15 per ADS on 12 February 2016 to establish the fair market value to meet tax liabilities following the vesting of awards granted in 2012 under the PSP.
Director/PDMR |
Number of ADSs withheld to meet tax liabilities following the vesting of a PSP award |
Dr M Slaoui* |
26,557 |
Mr N Hirons** |
1,390 |
Mr D Troy |
16,364 |
* Denotes an Executive Director
** Sale for tax of vested PSP awards granted under the non CET Performance Share Plan
The Company, Directors and PDMRs were advised of these transactions on 16 February 2016.
This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
V A Whyte
Company Secretary
16 February 2016